Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Triple Negative Breast Neoplasms 2 Ovarian Neoplasms 2 Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Advanced Nonhematologic Malignancies 2 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Somatostatinoma 1 Sarcoma, Synovial 1 Sarcoma 1 Recurrent Lung Squamous Cell Carcinoma 1 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Non-hematologic Malignancy 1 Neurofibrosarcoma 1 Neoplasm Metastasis 1 Metastatic Castration-Resistant Prostate Cancer 1 Meningeal Neoplasms 1 Lymphoma 1 Liver Neoplasms 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Hematologic Neoplasms 1 Glioblastoma 1 Fibrolamellar hepatocellular carcinoma 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1

Interventions

Rituximab 173 Cyclophosphamide 157 Vincristine 72 fludarabine phosphate 71 Doxorubicin 69 Etoposide 68 Prednisone 67 Filgrastim 58 Methotrexate 52 Cytarabine 51 fludarabine 49 Melphalan 48 Busulfan 47 Tacrolimus 41 Whole-Body Irradiation 39 Mycophenolic Acid 39 Granulocyte Colony-Stimulating Factor 37 Antilymphocyte Serum 31 Peripheral Blood Stem Cell Transplantation 30 Radiotherapy 27 Lenalidomide 25 Dexamethasone 25 Carmustine 23 Stem Cell Transplantation 22 Cyclosporine 22 Bortezomib 22 Gemcitabine 20 Bendamustine Hydrochloride 20 ibritumomab tiuxetan 19 Alemtuzumab 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Lymphoma × sapanisertib × Clear all

NCT02727777 2020-03-12

Phase II Study of TAK228 in Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated

4 enrolled 9 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡